Bayer has received approval from the European Commission of Kovaltry for the treatment of hemophilia A in patients of all...
The FDA has approved Bayer’s Kovaltry (recombinant Factor VIII), for the treatment of hemophilia A in children and adults. The...
New Phase III data from Bayer HealthCare's LEOPOLD Kids clinical trial investigating the safety and efficacy of BAY 81-8973, otherwise...
The objective of the trial is to demonstrate that 2-3 times per week prophylaxis therapy with BAY81-8973 is superior to...